Cargando…
Asymptomatic screening for SARS CoV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice.
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450924/ https://www.ncbi.nlm.nih.gov/pubmed/32928674 http://dx.doi.org/10.1016/j.dld.2020.08.035 |
| _version_ | 1783574887031373824 |
|---|---|
| author | Prentice, Ralley E. Al-Ani, Aysha H Bond, Katherine Johnson, Doug Christensen, Britt |
| author_facet | Prentice, Ralley E. Al-Ani, Aysha H Bond, Katherine Johnson, Doug Christensen, Britt |
| author_sort | Prentice, Ralley E. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7450924 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74509242020-08-28 Asymptomatic screening for SARS CoV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice. Prentice, Ralley E. Al-Ani, Aysha H Bond, Katherine Johnson, Doug Christensen, Britt Dig Liver Dis Correspondence Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l. 2020-11 2020-08-27 /pmc/articles/PMC7450924/ /pubmed/32928674 http://dx.doi.org/10.1016/j.dld.2020.08.035 Text en Crown Copyright © 2020 Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Correspondence Prentice, Ralley E. Al-Ani, Aysha H Bond, Katherine Johnson, Doug Christensen, Britt Asymptomatic screening for SARS CoV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice. |
| title | Asymptomatic screening for SARS CoV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice. |
| title_full | Asymptomatic screening for SARS CoV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice. |
| title_fullStr | Asymptomatic screening for SARS CoV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice. |
| title_full_unstemmed | Asymptomatic screening for SARS CoV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice. |
| title_short | Asymptomatic screening for SARS CoV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice. |
| title_sort | asymptomatic screening for sars cov-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice. |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450924/ https://www.ncbi.nlm.nih.gov/pubmed/32928674 http://dx.doi.org/10.1016/j.dld.2020.08.035 |
| work_keys_str_mv | AT prenticeralleye asymptomaticscreeningforsarscov2priortocommencementofbiologictherapiesinpatientswithinflammatoryboweldiseaseapotentiallyharmfulpractice AT alaniayshah asymptomaticscreeningforsarscov2priortocommencementofbiologictherapiesinpatientswithinflammatoryboweldiseaseapotentiallyharmfulpractice AT bondkatherine asymptomaticscreeningforsarscov2priortocommencementofbiologictherapiesinpatientswithinflammatoryboweldiseaseapotentiallyharmfulpractice AT johnsondoug asymptomaticscreeningforsarscov2priortocommencementofbiologictherapiesinpatientswithinflammatoryboweldiseaseapotentiallyharmfulpractice AT christensenbritt asymptomaticscreeningforsarscov2priortocommencementofbiologictherapiesinpatientswithinflammatoryboweldiseaseapotentiallyharmfulpractice |